Keen Therapeutics was recently founded aiming to become the next generation biotech in China. The Company is led by a group of spirited chemical biologist, biophysicist, immunologist, computational chemist, and algorithm engineer.
Enabled by first-principle-based computational methods, the Company focuses on challenging targets/pathways to provide innovative cancer therapies. Through collaboration with niche CROs that are more focused and efficient, the Company tries to minimize the time and cost for pre-clinical discovery.
The Company has made dedicated efforts and some progress in the area of cancer metabolism including ferroptosis. It is expected to nominate the first pre-clinical candidate by the end of 2022.
Company Details
- Employees
- 5
- Founded
- -
- Address
- 苏州市, 江苏省, Cn
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- HQ
- 苏州市, 江苏省
Keen Therapeutics Questions
Keen Therapeutics's LinkedIn profile is https://cn.linkedin.com/company/keen-therapeutics
Keen Therapeutics has
5 employees.
View email and phone details for 5
employees at Keen Therapeutics.
Keen Therapeutics's industry is
Biotechnology Research
Keen Therapeutics's top competitors are
Asylia Diagnostics Bv,
Retex Pharmaceuticals,
Veriphi,
Eirnabio,
Accellena R&d,
Cli Ventures,
D2m Biotherapeutics,
Kojin Therapeutics,
Fortitude Biomedicines,
Elba Discovery.
Keen Therapeutics's categories are Biotechnology Research
Keen Therapeutics's founding year is 2020
